recurrent glomerulonephritis; tubulointerstitial nephritis; injection-site pain; fatigue; This is a literature report.  A 35-year-old female patient received BNT162b2 (BNT162B2), on 29Jan2021 as dose 1, single (Batch/Lot number: unknown) and on 01Mar2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "IgA nephropathy", start date: Nov2016 (unspecified if ongoing), notes: with cellular and fibrous crescents.; "Psoriasis" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Mmf, stop date: May2019, for IgA nephropathy; High-dose steroids for IgA nephropathy. The following information was reported: GLOMERULONEPHRITIS (medically significant) with onset 18May2021, outcome "unknown", described as "recurrent glomerulonephritis"; TUBULOINTERSTITIAL NEPHRITIS (medically significant) with onset 18May2021, outcome "unknown"; FATIGUE (non-serious) with onset 2021, outcome "recovered"; PAIN (non-serious) with onset 2021, outcome "recovered", described as "injection-site pain". The patient underwent the following laboratory tests and procedures: Biopsy kidney: (unspecified date) showed focal segmental endocapillary, notes: hypercellularity, 20% of glomeruli with crescents including 3 cellular, 1 fibrocellular, and 1 fibrous. There was mesangial hypercellularity and 15% IFTA; (Nov2016) IgA nephropathy, notes: with cellular and fibrous crescents no significant IFTA; (17Aug2021) IgA nephropathy, notes: with cellular and fibrous crescents; Blood creatinine: (unspecified date) 0.9-1.0 mg/dl; (unspecified date) 1.13 mg/dl, notes: 8 weeks after the second dose; (Nov2020) 1 mg/dl; (unspecified date) 1.1 mg/dl; (unspecified date) 1.1 mg/dl; (unspecified date) 1.10 mg/dl, notes: Four weeks later, remained stable; Immunology test: (unspecified date) Dominantly diffuse mesangial, notes: and focal segmental capillary wall granular IgA staining (4+) was noted; Oxford classification Score: (unspecified date) M1, E1, S1, T0, and C1; Microscopy: (unspecified date) there were numerous, notes: mesangial/paramesangial EDD; Protein urine: (unspecified date) 1.3 g, notes: initially noted; Urine protein/creatinine ratio: (unspecified date) 1.1 g; (unspecified date) 2 g, notes: further increased to 2 g 2 months later; Urine protein/creatinine ratio: (Nov2020) 0.36, notes: Unit: g/g (Baseline proteinuria); Urine protein/creatinine ratio: (unspecified date) 2000 mg/g, notes: Peak proteinuria; (unspecified date) 1143 mg/g, notes: Nadir proteinuria; (unspecified date) 1143 mg/g, notes: Four weeks later. Therapeutic measures were taken as a result of glomerulonephritis, tubulointerstitial nephritis. ; Sender's Comments: Based on the information in the case report, a possible causal relationship between reported events and suspect drug BNT162B2 cannot be excluded  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate,Linked Report(s) : US-PFIZER INC-PV202200019158 Same article/ drug/event and different patient;